De novo DDX3X missense variants in males appear viable and contribute to syndromic intellectual disability.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
04 2019
Historique:
received: 12 09 2018
revised: 12 12 2018
accepted: 04 01 2019
pubmed: 9 2 2019
medline: 23 4 2020
entrez: 9 2 2019
Statut: ppublish

Résumé

DDX3X (Xp11.4) encodes a DEAD-box RNA helicase that escapes X chromosome inactivation. Pathogenic variants in DDX3X have been shown to cause X-linked intellectual disability (ID) (MRX102, MIM: 300958). The phenotypes associated with DDX3X variants are heterogeneous and include brain and behavioral abnormalities, microcephaly, hypotonia, and movement disorders and/or spasticity. The majority of DDX3X variants described are de novo mutations in females with ID. In contrast, most male DDX3X variants are inherited from an unaffected mother, with one documented exception being a recently identified de novo splice site variant. It has been suggested, therefore, that DDX3X exerts its effects through haploinsufficiency in females, and that affected males carry hypomorphic alleles that retain partial function. Given the lack of male de novo DDX3X variants, loss-of-function variants in this gene are suspected to be male lethal. Through whole-exome sequencing, we identified three unrelated males with hemizygous missense DDX3X variants and ID. All three variants were confirmed by Sanger sequencing, with two established as de novo. In silico analyses were supportive of pathogenicity. We report the male phenotypes and compare them to phenotypes observed in previously reported male and female patients. In conclusion, we propose that de novo DDX3X variants are not necessarily male lethal and should be considered as a cause of syndromic ID in both males and females.

Identifiants

pubmed: 30734472
doi: 10.1002/ajmg.a.61061
doi:

Substances chimiques

DDX3X protein, human EC 3.6.1.-
DEAD-box RNA Helicases EC 3.6.4.13

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-578

Subventions

Organisme : Health Innovation Challenge Fund
ID : HICF-1009-003
Pays : International
Organisme : Wellcome Sanger Institute
ID : WT098051
Pays : International
Organisme : Mayo Clinic
Pays : International
Organisme : National Institute for Health Research
Pays : International
Organisme : Department of Health [UK]
ID : WT098051
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Pantelis Nicola (P)

University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom.
Manchester Centre for Genomic Medicine, Manchester, United Kingdom.

Patrick R Blackburn (PR)

Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Kristen J Rasmussen (KJ)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Nicole L Bertsch (NL)

Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota.

Eric W Klee (EW)

Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota.

Linda Hasadsri (L)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Pavel N Pichurin (PN)

Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota.

Julia Rankin (J)

Clinical Genetics Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom.

F Lucy Raymond (FL)

Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Deciphering Developmental Disorders Study (DDD), Wellcome Sanger Institute, Cambridge, United Kingdom.

Jill Clayton-Smith (J)

Manchester Centre for Genomic Medicine, Manchester, United Kingdom.
Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH